Adult Dosing

Immunization against influenza H5N1 virus

• Administer 1 mL IM once; administer second 1 mL dose 28 days later (range 21-35 days)

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Active immunization of patients aged 18 through 64 years at increased risk of exposure to the H5N1 influenza virus

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Influenza virus vaccine, H5N1 contains chicken and egg proteins. Use cautiously in patients with a history of a hypersensitivity reaction to chicken or egg proteins or life-threatening reactions to previous influenza vaccinations
• Persons known to have experienced Guillain-Barré syndrome within 6 wk after a previous influenza vaccination should not receive influenza virus vaccine, unless the benefit outweighs the risk
• Immunocompromised persons, including those receiving immunosuppressive therapy may have a reduced antibody response to inactivated influenza vaccine and may remain susceptible despite immunization
• Anaphylactic reactions can occur, appropriate medical treatment and supervision should be readily available to manage possible anaphylactic reactions
• The tip of prefilled syringe contains natural rubber latex which can cause allergic reactions in latex sensitive individuals
• To avoid the risk of hematoma following the injection, use cautiously in patients with bleeding disorders such as hemophilia or in those on anticoagulant therapy

Pregnancy Category:C

Breastfeeding: The Centers for Disease Control and Prevention states that vaccines given to a nursing mother do not affect breastfed infants and breastfeeding is not a contraindication to influenza vaccine. This information is based upon LactMed database (available at

• CNS: Headache, malaise, fever, pyrexia
• MUSC: Pain, tenderness, myalgia
• DERM: Erythema/redness, swelling
• EENT: Nasopharyngitis, nasal congestion
• RESP: Upper respiratory tract infection, pharyngolaryngeal pain
• GI: Nausea, diarrhea

• Vaccine; forms specific antibodies that protect against influenza H5N1 and blocks viral attachment to human respiratory cells
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Influenza H5N1 vaccine

US Availability

Influenza H5N1 vaccine

• INJ: 5 mL multidose vial

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Immunologic

Vaccines

Viral